The effect of etanercept and infliximab on the production of @entity5 @entity39 factor alpha, @entity379 and XXXX in in vivo activated intestinal T lymphocyte cultures.

@entity1 @entity2841 @entity39 @entity5 @entity310 @entity379 @entity30 @entity309
BACKGROUND/AIMS: Infliximab (Ifx) is effective in the treatment of @entity30 ( @entity30 ) and @entity309 ( @entity309 ), etanercept (Eta) in @entity309 but not in @entity30 . The mechanisms underlying these clinical differences are not fully understood, but this knowledge could be valuable to identify responders and develop new treatments. This study compares Eta and Ifx in vitro regarding transmembrane @entity5 @entity39 factor alpha (tmb- @entity310 ) expression and @entity379 ( @entity379 ), @entity310 and @entity2841 ( @entity2841 ) production in intestinal T lymphocytes. METHODS: T lymphocyte cultures were established from biopsies from 10 @entity30 @entity1 and three healthy controls. The cytokine production and the expression of tmb- @entity310 were measured in the presence of Ifx/Eta. RESULTS: Eta and Ifx downregulated the production of @entity379 and @entity2841 in colonic T lymphocytes from @entity30 @entity1 and healthy controls. Both drugs bound tmb- @entity310 on activated T lymphocytes besides neutralising @entity310 , Eta less efficiently than Ifx (406 pg/ml (337-475); 133 pg/ml (119-147); p=0.004). @entity310 was detectable with the present assay in cell lines cultured in the presence of excess Eta. CONCLUSIONS: We have established that Eta is just as efficient as Ifx in downregulating @entity379 and @entity2841 production in vitro and Eta bound to tmb- @entity310 . However, Eta bound the @entity310 molecule, important in @entity30 , less efficiently than Ifx.
